Inovio

Selected news for the company - Inovio, collected since 10/2017. Recent stories appear in The Markets Daily and dailymagazine.news. This company shares news with Moderna, COVID-19, J. Joseph Kim, Joseph Kim, Pfizer and hundreds of others.

Please provide a valid email address.

Selected Headines

Date Headline (link) Source Relevant Snippet
1/10/2021 Analysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $12.80 The Markets Daily Analysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $12.80 Posted by Michael WalenShares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned a consensus rating of “Hold” from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, five have given a hold recommendation and two have assigned a buy recommendation to the company. The ...
1/7/2021 Inovio: Advaccine Deal Is a Positive but Not a Game Changer, Analyst Says dailymagazine.news ... second half was marred by disappointment as the company failed to keep up with the pace setters. No doubt, in 2021, investors would like a repeat of last year's initial surge.Meanwhile, on Monday, Inovio announced a collaboration and licensing deal for its COVID-19 DNA vaccine candidate INO-4800.The company has partnered with China-based Advaccine Biopharmaceuticals who will own the exclusive rights to develop, produce and bring ...
1/6/2021 Inovio, Advaccine Forge Pact to Sell COVID-19 Vaccine in China fdanews.com Home » Inovio , Advaccine Forge Pact to Sell COVID-19 Vaccine in China Inovio , Advaccine Forge Pact to Sell COVID-19 Vaccine in China January 6, 2021Pennsylvania-based Inovio has teamed up with Chinese biotech Advaccine to market its COVID-19 vaccine candidate, INO-4800, in China.Per the deal, Advaccine will receive exclusive development, production and marketing rights for the vaccine in China, Hong Kong, Macao and Taiwan ...
1/6/2021 INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18 PR Newswire ... By comparison, the spontaneous resolution of vulvar HSIL caused by HPV-16/18 is estimated to be only 2%. The trial also showed VGX-3100 to be safe and well-tolerated. Based upon these results INOVIO is planning to pursue Phase 3 development. Dr. Robert Edwards , MD, Milton Lawrence McCall Professor and Chair, Department of Obstetrics, Gynecology & Reproductive Sciences, University of Pittsburgh and Principal Coordinating Investigator for the Phase 2 clinical ...
1/5/2021 Inovio Pharmaceuticals (NASDAQ:INO) Stock Price Up 9.9% slatersentinel.com ... trading, a decline of 43% from the average daily volume of 25,758,137 shares. The stock had previously closed at $8.85.INO has been the subject of several research reports. Cantor Fitzgerald cut shares of Inovio Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $31.00 to $12.00 in a research report on Monday, September 28th. Maxim Group raised shares ...
1/5/2021 Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of "Hold" from Analysts | MarketBeat marketbeat.com ... that have covered the stock in the last year is $12.80. How to Invest After a Turbulent 2020 ElectionINO has been the topic of several research analyst reports. Maxim Group upgraded shares of Inovio Pharmaceuticals from a "hold" rating to a "buy" rating and set a $20.00 price objective on the stock in a research report on Monday, September 28th. BidaskClub lowered Inovio Pharmaceuticals from a "sell" rating to ...
1/5/2021 Inovio and Advaccine Partner to Commercialize COVID-19 Vaccine in China fdanews.com Home » Inovio and Advaccine Partner to Commercialize COVID-19 Vaccine in China Inovio and Advaccine Partner to Commercialize COVID-19 Vaccine in China January 5, 2021Pennsylvania-based Inovio has teamed up with Chinese biotech Advaccine to market its COVID-19 vaccine candidate, INO-4800, in China.Per the deal, Advaccine will receive exclusive development, production and marketing rights for the vaccine in China, Hong Kong, Macao and Taiwan ...
1/5/2021 Analysts Have Conflicting Sentiments on These Healthcare Companies: DENTSPLY SIRONA (XRAY), Inovio Pharmaceuticals (INO) and Atara Biotherapeutics (ATRA) analystratings.com Analysts have been eager to weigh in on the Healthcare sector with new ratings on DENTSPLY SIRONA ( XRAY – Research Report ), Inovio Pharmaceuticals ( INO – Research Report ) and Atara Biotherapeutics ( ATRA – Research Report ).DENTSPLY SIRONA (XRAY)H.C. Wainwright analyst Yi Chen reiterated a Hold rating on DENTSPLY SIRONA today and set a price target of $55.00 . The company’s shares closed last Monday at $53.75.According to TipRanks.com , Chen ...
1/5/2021 Chick-fil-A to open new west Las Vegas location on Thursday ruthcgreene.com ... every county in Pennsylvania continuing to have a substantial risk of community spread of COVID-19. A report released Monday showed that, despite improving case numbers statewide, all 67 counties in the state Inovio stock jumps on news of licensing deal with Advaccine for Covid-19 vaccine candidateInovio said Monday it has entered into a collaboration and license agreement with Advaccine Biopharmaceuticals Suzhou Co. Ltd. for its Covid ...
1/5/2021 Trends Of Coronavirus Vaccine Market Reviewed For 2020 With Industry Outlook To 2029 5gigs.com Thomas Gideon Leave a Comment on Trends Of Coronavirus Vaccine Market Reviewed For 2020 With Industry Outlook To 2029The Global Coronavirus Vaccine Market report, distributed by Stats and Reports, is a broad compilation of the basic parts of the worldwide Coronavirus Vaccine Coronavirus Vaccine Coronavirus Vaccine Market report: https://marketresearch.biz/report/coronavirus-vaccine- Coronavirus Vaccine Coronavirus Vaccine Market.Adapting to the recent novel COVID-19 pandemic, the impact of ...
1/5/2021 Plymouth Meeting-based Inovio Signs Licensing Agreement with China's Advaccine for Its COVID-19 DNA Vaccine Candidate montco.today Published: 5:08 7:55Plymouth Meeting-based Inovio saw its stock jump after signing a collaboration and license agreement with Advaccine Biopharmaceuticals Suzhou for its COVID-19 DNA vaccine candidate, writes John George for the Philadelphia Business Journal .The deal, which carries a potential value of over $110 million, gives Advaccine the exclusive right to develop, manufacture, and commercialize Inovio’s experimental vaccine within Greater China.Additionally, the China-based company ...
1/5/2021 Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of “Hold” from Analysts Ticker Report ... The average 1-year target price among analysts that have covered the stock in the last year is $12.80.INO has been the topic of several research analyst reports. Maxim Group upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Monday, September 28th. BidaskClub lowered Inovio Pharmaceuticals from a “sell ...
1/4/2021 Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Expected to Post Quarterly Sales of $1.02 Million theenterpriseleader.com Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Expected to Post Quarterly Sales of $1.02 Million Posted by Marion Hillson on Jan 3rd, 2021Wall Street analysts predict that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) will post $1.02 million in sales for the current quarter, Zacks reports. Four analysts have issued estimates for Inovio Pharmaceuticals’ earnings. The lowest sales estimate is $230,000.00 and the highest is $2.30 million. Inovio Pharmaceuticals posted sales of ...
1/4/2021 Triple Combo With Libtayo Shows Promise in Hard-to-treat Brain Cancer bionewsfeeds.com ... immune responses and shows early signs of effectiveness in adults newly diagnosed with glioblastoma — the most aggressive type of brain cancer — according to interim data from a Phase 1/2 trial. Developed by Inovio Pharmaceuticals, the DNA-based vaccines, called INO-5401 and INO-9012, are meant to boost anti-tumor immune responses, which can lead to cancer cell death. Participants started the triple immunotherapy after surgery†...
1/4/2021 Inovio expects to begin late-stage Covid-19 vaccine study in second-quarter 2021 pharmalive.com Business , China , Clinical Trials , Drug Delivery , R&D , Shares , United States Inovio expects to begin late-stage COVID-19 vaccine study in second quarter (Reuters) – Inovio Pharmaceuticals Inc expects to start a late-stage U.S. study of its experimental COVID-19 vaccine candidate in the second quarter of 2021, the drug developer’s chief executive officer said on Monday. Inovio ’s vaccine, INO-4800, is being tested in two ...
1/4/2021 INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China PR Newswire PLYMOUTH MEETING, Pa. and SUZHOU, China , Jan. 4, INOVIO (NASDAQ: INO ), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("Advaccine"), an emerging biotech company with next-generation technology in vaccines, both preventive and therapeutic, today announced that they have entered into a collaboration and license agreement for COVID-19 DNA ...
1/4/2021 INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China PR Newswire ... right to develop, manufacture and commercialize INO-4800 within Greater China , inclusive of Mainland China, Hong Kong , Macao , and Taiwan . Advaccine will license its plasmid manufacturing process for use with INO-4800 and other INOVIO pipeline product candidates to INOVIO with the right to sublicense to INOVIO's manufacturing partners. Additionally, Advaccine will provide its clinical data to INOVIO in support of INOVIO's global INO-4800 regulatory filings and INOVIO will ...
1/4/2021 Inovio partners with Advaccine to make and sell COVID-19 vaccine in China srnnews.com Reuters) – China’s Advaccine Biopharmaceuticals Suzhou Co Ltd will manufacture and sell Inovio Pharmaceuticals Inc’s COVID-19 vaccine candidate in the country, the companies said on Monday.Advaccine will have the exclusive right to Inovio ’s vaccine candidate, INO-4800, in China. The vaccine is currently being tested in two mid-to-late stage trials, one in China and the other in the United States.Inovio will receive ...
1/4/2021 Inovio partners with Advaccine to make and sell COVID-19 vaccine in China wxerfm.com Inovio partners with Advaccine to make and sell COVID-19 vaccine in China Jan 4, 2021 8:01 AM(Reuters) - China's Advaccine Biopharmaceuticals Suzhou Co Ltd will manufacture and sell Inovio Pharmaceuticals Inc's COVID-19 vaccine candidate in the country, the companies said on Monday.Advaccine will have the exclusive right to Inovio 's vaccine candidate, INO-4800, in China. The vaccine is currently being tested in two mid-to-late stage ...
1/4/2021 Inovio partners with Advaccine to make and sell COVID-19 vaccine in China kelofm.com Inovio partners with Advaccine to make and sell COVID-19 vaccine in China / 101.9 KELO-FM Jan 4, 2021 8:01 AM(Reuters) - China's Advaccine Biopharmaceuticals Suzhou Co Ltd will manufacture and sell Inovio Pharmaceuticals Inc's COVID-19 vaccine candidate in the country, the companies said on Monday.Advaccine will have the exclusive right to Inovio 's vaccine candidate, INO-4800, in China. The vaccine is currently being tested in two mid ...